[go: up one dir, main page]

PT2376116E - Anticorpos anti-igf - Google Patents

Anticorpos anti-igf Download PDF

Info

Publication number
PT2376116E
PT2376116E PT97713614T PT09771361T PT2376116E PT 2376116 E PT2376116 E PT 2376116E PT 97713614 T PT97713614 T PT 97713614T PT 09771361 T PT09771361 T PT 09771361T PT 2376116 E PT2376116 E PT 2376116E
Authority
PT
Portugal
Prior art keywords
igf antibodies
igf
antibodies
Prior art date
Application number
PT97713614T
Other languages
English (en)
Inventor
Paul Adam
Eric Borges
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40512371&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2376116(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PT2376116E publication Critical patent/PT2376116E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT97713614T 2008-12-12 2009-12-11 Anticorpos anti-igf PT2376116E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08171554 2008-12-12

Publications (1)

Publication Number Publication Date
PT2376116E true PT2376116E (pt) 2016-02-24

Family

ID=40512371

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97713614T PT2376116E (pt) 2008-12-12 2009-12-11 Anticorpos anti-igf

Country Status (38)

Country Link
US (4) US8318159B2 (pt)
EP (2) EP2376116B1 (pt)
JP (2) JP5694184B2 (pt)
KR (1) KR101827332B1 (pt)
CN (3) CN102227226B (pt)
AP (1) AP3371A (pt)
AR (1) AR074726A1 (pt)
AU (1) AU2009324296B2 (pt)
BR (1) BRPI0923359B8 (pt)
CA (1) CA2740341C (pt)
CL (1) CL2011001431A1 (pt)
CO (1) CO6390042A2 (pt)
CY (1) CY1117241T1 (pt)
DK (1) DK2376116T3 (pt)
EA (1) EA029178B1 (pt)
EC (1) ECSP11011126A (pt)
ES (1) ES2561045T3 (pt)
GE (1) GEP20146119B (pt)
HR (1) HRP20160190T1 (pt)
HU (1) HUE026374T2 (pt)
IL (1) IL212047A (pt)
MA (1) MA32888B1 (pt)
ME (1) ME02377B (pt)
MX (1) MX2011006055A (pt)
MY (1) MY150984A (pt)
NZ (3) NZ597694A (pt)
PE (1) PE20120415A1 (pt)
PL (1) PL2376116T3 (pt)
PT (1) PT2376116E (pt)
RS (1) RS54423B1 (pt)
SG (2) SG2014013841A (pt)
SI (1) SI2376116T1 (pt)
TN (1) TN2011000299A1 (pt)
TW (1) TWI471139B (pt)
UA (1) UA105198C2 (pt)
UY (1) UY32317A (pt)
WO (1) WO2010066868A2 (pt)
ZA (1) ZA201102308B (pt)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2066694T1 (sl) * 2006-09-29 2016-02-29 Oncomed Pharmaceuticals, Inc. Sestavki in postopki za diagnosticiranje in zdravljenje raka
PE20090368A1 (es) * 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
ES2719728T3 (es) 2007-09-04 2019-07-12 Compugen Ltd Polipéptidos y polinucleótidos, y usos de los mismos como una diana farmacológica para producir fármacos y agentes biológicos
CN102232087A (zh) 2008-11-10 2011-11-02 诺瓦提斯公司 修饰的人igf-1/e肽的抗体
CN102227226B (zh) 2008-12-12 2015-05-13 贝林格尔.英格海姆国际有限公司 抗igf抗体
TR201818814T4 (tr) 2009-10-16 2019-01-21 Oncomed Pharm Inc Dll4 antagonist antikorlarının ve anti-hipertansif ajanların terapötik kombinasyonu ve kullanımı.
EP2494070A2 (en) * 2009-10-30 2012-09-05 Bristol-Myers Squibb Company Methods for treating cancer in patients having igf-1r inhibitor resistance
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
EP2640421A4 (en) * 2010-11-16 2014-05-28 Medimmune Llc THERAPIES FOR TREATMENTS WITH ANTI-IGF ANTIBODIES
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US9428574B2 (en) 2011-06-30 2016-08-30 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
PT3485903T (pt) * 2011-09-23 2023-02-17 Mereo Biopharma 5 Inc Agentes de ligação a vegf/dll4 e utilizações dos mesmos
WO2013060872A1 (en) * 2011-10-27 2013-05-02 Boehringer Ingelheim International Gmbh Anticancer combination therapy
KR20140126357A (ko) 2012-02-01 2014-10-30 컴퓨젠 엘티디. C1orf32 항체 및 이의 암 치료를 위한 용도
EP3542861A1 (en) * 2012-09-25 2019-09-25 Bioverativ Therapeutics Inc. Methods of using fix polypeptides
CN102863530A (zh) * 2012-09-26 2013-01-09 李彬 一种脂肪细胞分化代谢产物igf-1抗体及包含该抗体的芯片以及应用
CA2889638A1 (en) 2012-10-31 2014-05-08 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a dll4 antagonist
US20140255413A1 (en) * 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
JP2016528167A (ja) 2013-04-29 2016-09-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ヒトＦｃＲｎ結合改変抗体及び使用方法
CN105164157B (zh) 2013-04-29 2024-05-28 豪夫迈·罗氏有限公司 Fc-受体结合的修饰的非对称抗体及使用方法
CN106029690B (zh) * 2013-10-18 2021-08-31 诺瓦塞浦加工有限公司 蛋白质纯化
US20160324962A1 (en) * 2013-12-19 2016-11-10 Medimmune, Llc Compositions and methods for treating sarcoma
WO2015107015A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with improved protein a-binding
SI3096792T1 (sl) * 2014-01-24 2020-01-31 Boehringer Ingelheim International Gmbh Zdravljenje raka z uporabo antagonista receptorja insulinu podobnega rastnega faktorja (IGF) v kombinaciji z eksemestanom in everolimusom
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
ES2808153T3 (es) 2014-10-31 2021-02-25 Mereo Biopharma 5 Inc Terapia de combinación para tratamiento de enfermedad
US20180104332A1 (en) * 2015-01-16 2018-04-19 The University Of Liverpool Insulin-like growth factor inhibitor and chemotherapeutic agent for use in cancer therapy
WO2017035430A2 (en) * 2015-08-27 2017-03-02 Kolltan Pharmaceuticals, Inc. Anti-alk antibodies and methods for use thereof
AU2016326609B2 (en) 2015-09-23 2023-03-09 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
US20170088609A1 (en) 2015-09-28 2017-03-30 Boehringer Ingelheim International Gmbh Anticancer combination therapy
CN105622730B (zh) * 2016-02-18 2020-06-26 深圳华尔康生物科技有限公司 一种特异性结合igf-1的多肽及其应用
EP3878850A1 (en) 2016-12-22 2021-09-15 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
EA039807B1 (ru) 2017-01-06 2022-03-16 ЭйБиЭл БИО ИНК. Антитело к -синуклеину и его применение
WO2019063802A1 (en) 2017-09-29 2019-04-04 Boehringer Ingelheim International Gmbh ANTICANCER ANTI-IGF POLY THERAPY, ANTI PD-1
CN116731173A (zh) 2017-12-14 2023-09-12 Abl生物公司 抗a-syn/igf1r的双特异性抗体及其用途
DK3728254T3 (da) 2017-12-21 2023-06-06 Boehringer Ingelheim Int Benzylamin-substituerede pyridopyrimidinoner og derivater som sos1-inhibitorer
KR102404684B1 (ko) * 2019-01-15 2022-06-07 서울대학교산학협력단 인슐린 유사 성장인자 2 억제제를 포함하는 만성 폐질환의 예방 또는 치료용 조성물
US20230212164A1 (en) 2020-06-02 2023-07-06 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CA3203111A1 (en) 2020-12-22 2022-06-30 Kailiang Wang Sos1 inhibitors and uses thereof
EP4328219A4 (en) 2021-04-23 2024-11-27 Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. SOS1 DEGRADING AGENT, ITS PREPARATION PROCESS AND ITS USE
WO2023099620A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
EP4441054A1 (en) 2021-12-01 2024-10-09 Boehringer Ingelheim International GmbH Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
JP2024543967A (ja) 2021-12-01 2024-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ガン処置のための環化２－アミノ－３－シアノチオフェン及び誘導体
TW202340209A (zh) 2021-12-01 2023-10-16 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
CN118613485A (zh) 2021-12-01 2024-09-06 勃林格殷格翰国际有限公司 用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物
EP4441050A1 (en) 2021-12-01 2024-10-09 Boehringer Ingelheim International GmbH Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CN114671949B (zh) * 2022-04-20 2023-04-28 山西农业大学 一种igf1纳米抗体及其应用
KR20250016223A (ko) * 2022-05-20 2025-02-03 레졸루트 인크 항인슐린 수용체 항체를 위한 제형 및 이의 용도
KR20240053520A (ko) * 2022-10-14 2024-04-24 포항공과대학교 산학협력단 Igf-1 수용체 결합 압타머 및 이의 용도
WO2024083256A1 (zh) 2022-10-21 2024-04-25 上海领泰生物医药科技有限公司 pan-KRAS降解剂及其制备方法和应用
WO2024083258A1 (zh) 2022-10-21 2024-04-25 上海领泰生物医药科技有限公司 Kras g12d降解剂及其制备方法和应用
TW202504611A (zh) 2023-03-30 2025-02-01 美商銳新醫藥公司 用於誘導ｒａｓ ｇｔｐ水解之組合物及其用途
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2024246099A1 (en) 2023-05-30 2024-12-05 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
GB2631397A (en) 2023-06-28 2025-01-08 Sevenless Therapeutics Ltd New treatments for pain
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
GB2633813A (en) 2023-09-21 2025-03-26 Sevenless Therapeutics Ltd New treatments for pain
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025083426A1 (en) 2023-10-20 2025-04-24 Sevenless Therapeutics Limited New treatments for pain
WO2025137507A1 (en) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof
WO2025146548A1 (en) 2024-01-04 2025-07-10 Sevenless Therapeutics Limited Sos1 inhibitors useful to treat pain and cancer
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025210041A1 (en) 2024-04-03 2025-10-09 Boehringer Ingelheim International Gmbh Bicyclic benzylamido pyridine derivatives as sos1 inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
ATE220101T1 (de) 1983-04-25 2002-07-15 Chiron Corp Hybrid-dns-synthesis von reifen insulinähnlichen wachstumsfaktoren
WO1985000831A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
AU1232188A (en) 1987-05-29 1988-12-01 Mallinckrodt, Inc. Novel pair of monoclonal antibodies to insulin-like growth factor i permits immunometric assay for igf-i
EP0417193B1 (en) 1988-05-27 1993-08-04 Centocor, Inc. Freeze-dried formulation for antibody products
EP0378671B1 (en) 1988-06-30 1997-03-12 City Of Hope Insulinomimetic and insulin receptor binding site peptides
CA2058041A1 (en) 1990-06-27 1991-12-28 Katsuichi Sakano Anti-igf-ii monoclonal antibody
WO1994029347A1 (en) 1993-06-03 1994-12-22 Therapeutic Antibodies Inc. Antibody fragments in therapy
EP0700994A1 (en) * 1994-03-23 1996-03-13 Japan Clinical Laboratories Anti-igf-i monoclonal antibody
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US7020563B1 (en) 1997-11-27 2006-03-28 Commonwealth Scientific And Industrial Research Organisation Method of designing agonists and antagonists to IGF receptor
MXPA01010891A (es) 1999-04-28 2002-11-07 Univ Texas Composiciones y metodos para el tratamiento contra el cancer mediante la inhibicion selectiva del factor de crecimiento endotelial vascular (vegf).
MA26040A1 (fr) 2001-01-05 2004-04-01 Pfizer Des anticorps pour recepteur i de facteur de croissance insulinique
CN1911965B (zh) 2001-01-17 2013-05-29 新兴产品开发西雅图有限公司 结合域-免疫球蛋白融合蛋白
EP1399484B1 (en) 2001-06-28 2010-08-11 Domantis Limited Dual-specific ligand and its use
WO2003050531A2 (en) 2001-12-11 2003-06-19 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
EP1798242B1 (fr) 2002-01-18 2013-01-23 Pierre Fabre Medicament Anticorps anti-IGF-IR et leurs applications
WO2003093317A1 (en) 2002-04-30 2003-11-13 Kyowa Hakko Kogyo Co., Ltd. Antibody to human insulin-like growth factor
JP2003310275A (ja) 2002-04-30 2003-11-05 Kyowa Hakko Kogyo Co Ltd ヒトインスリン様成長因子に対する遺伝子組換え抗体
EP2316921B1 (en) 2002-05-24 2014-05-14 Merck Sharp & Dohme Corp. Neutralizing human anti-IGFR antibody
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
DE60305919T2 (de) 2002-06-28 2007-01-18 Domantis Limited, Cambridge Dual-specifische liganden mit erhöhter halbwertszeit
US20030138430A1 (en) * 2002-09-20 2003-07-24 Stimmel Julie Beth Pharmaceutical comprising an agent that blocks the cell cycle and an antibody
EP1578801A2 (en) 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
EP1596885A2 (en) 2003-02-13 2005-11-23 Pfizer Products Inc. Uses of anti-insulin-like growth factor i receptor antibodies
CA2518980A1 (en) 2003-03-14 2004-09-30 Pharmacia Corporation Antibodies to igf-i receptor for the treatment of cancers
JP2007535895A (ja) 2003-05-01 2007-12-13 イムクローン システムズ インコーポレイティド ヒトインシュリン様成長因子−１受容体に対する完全ヒト抗体
AR046071A1 (es) 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
EP1661582A1 (en) 2003-08-21 2006-05-31 Kyowa Hakko Kogyo Co., Ltd. Cancer metastasis inhibitor
WO2005028515A1 (ja) 2003-09-24 2005-03-31 Kyowa Hakko Kogyo Co., Ltd. ヒトインスリン様成長因子に対する遺伝子組換え抗体
WO2005027970A1 (ja) 2003-09-24 2005-03-31 Kyowa Hakko Kogyo Co., Ltd. 癌治療用医薬
WO2005058967A2 (en) 2003-12-16 2005-06-30 Pierre Fabre Medicament Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
WO2006125640A2 (en) 2005-05-24 2006-11-30 Morphosys Ag Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
MX2007000610A (es) 2004-07-16 2007-03-07 Pfizer Prod Inc Tratamiento de combinacion para enfermedades malignas no hematologicas usando un anti-cuerpo de receptor de factor i de crecimiento de tipo anti-insulina.
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
HUE035250T2 (hu) * 2005-10-12 2018-05-02 Morphosys Ag Humán CD38-ra specifikus teljesen humán HuCAL GOLD-eredetû terápiás ellenanyagok létrehozása és profilozása
DK1979001T3 (da) * 2005-12-13 2012-07-16 Medimmune Ltd Bindingsproteiner, der er specifikke for insulinlignende vækstfaktorer og anvendelser deraf
CN101484587B (zh) 2006-02-03 2014-02-12 英克隆有限责任公司 Igf-ir拮抗剂作为辅药用于前列腺癌的治疗
BRPI0709843A2 (pt) 2006-03-28 2011-07-26 Biogen Idec Inc anticorpos de anti-igf-1r e usos dos mesmos
JP2009533028A (ja) * 2006-04-07 2009-09-17 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ 新生物疾患の治療のための抗体組成物および方法
US20080014203A1 (en) 2006-04-11 2008-01-17 Silke Hansen Antibodies against insulin-like growth factor I receptor and uses thereof
SI2027470T1 (sl) 2006-06-02 2013-01-31 Pfizer Products Inc. Analiza kroĺ˝eäśe tumorske celice
ES2427924T3 (es) 2006-06-30 2013-11-04 Merck Sharp & Dohme Corp. Biomarcador IGFBP2
US7749966B2 (en) 2006-12-21 2010-07-06 Boston Biomedical Research Institute Immunological modulation of insulin-like growth factor 1 for cancer prevention/treatment and prolonging longevity
AR064464A1 (es) 2006-12-22 2009-04-01 Genentech Inc Anticuerpos anti - receptor del factor de crecimiento insulinico
GB0702888D0 (en) 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
MX2009009379A (es) 2007-03-02 2009-09-14 Amgen Inc Metodos y composiciones para tratar enfermedades tumorales.
WO2008115470A2 (en) 2007-03-16 2008-09-25 East Carolina University Hox-gene expression as a biomarker for igf-1r therapeutics
BRPI0809112A2 (pt) 2007-03-22 2014-08-26 Imclone Llc Formulações estáveis de anticorpos
EP2559771A3 (en) 2007-05-17 2013-06-12 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
WO2008144720A2 (en) 2007-05-21 2008-11-27 University Of Washington Inhibitors of igf-1r signaling for the treatment of respiratory disorders
WO2008152422A2 (en) 2007-06-12 2008-12-18 Astrazeneca Ab Binding proteins specific for insulin-like growth factors and uses thereof-909
PE20090368A1 (es) * 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
US20110014117A1 (en) 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
WO2009006336A1 (en) 2007-06-28 2009-01-08 Sylgen Laboratories, Inc. Compositions and methods for inhibiting angiogenesis and tumorigenesis
JP2010535710A (ja) 2007-07-31 2010-11-25 メルク・シャープ・エンド・ドーム・コーポレイション 細胞増殖性疾患の検出及び診断に有用なｉｇｆ−１ｒ特異抗体
CN101855244A (zh) 2007-08-01 2010-10-06 葛兰素集团有限公司 新型抗体
EP2183275B1 (en) 2007-08-03 2014-10-29 Affibody AB Igf-1r binding polypeptides and their use
US8420315B2 (en) 2007-08-06 2013-04-16 Orion Genomics Llc Single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the IGF2 gene
EP2190480A4 (en) 2007-08-28 2013-01-23 Biogen Idec Inc ANTI-IGR-1R ANTIBODIES AND ITS USES
CA2697922A1 (en) 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Compositions that bind multiple epitopes of igf-1r
JP2010538680A (ja) 2007-09-19 2010-12-16 ザ トラスティーズ オブ ボストン ユニバーシティー 肺疾患に対する薬剤開発のための新規経路の同定
CA2694154A1 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2009045389A2 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
TWI580694B (zh) 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
CA2709827A1 (en) 2007-12-18 2009-06-25 Schering Corporation Biomarkers for sensitivity to anti-igf1r therapy
US20090258365A1 (en) 2008-03-25 2009-10-15 Terstappen Leon W M M METHOD FOR DETECTING IGF1R/Chr 15 in CIRCULATING TUMOR CELLS USING FISH
JP2011516549A (ja) 2008-04-11 2011-05-26 バイオジェン アイデック マサチューセッツ インコーポレイテッド 抗ｉｇｆ−１ｒ抗体と他の化合物との治療的併用
US20110129456A1 (en) 2008-05-05 2011-06-02 Yaolin Wang Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
AU2009244091B2 (en) 2008-05-09 2014-11-27 Commonwealth Scientific And Industrial Research Organisation IGF-II/GF-IIE binding proteins
EP2297208A4 (en) 2008-06-03 2012-07-11 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
MX2011003133A (es) 2008-09-26 2011-04-21 Roche Glycart Ag Anticuerpos biespecificos anti-egfr/anti-igf-1r.
JP2012503487A (ja) 2008-09-26 2012-02-09 シェーリング コーポレイション 高力価抗体の製造
CA2740440A1 (en) 2008-10-14 2010-04-22 Dyax Corp. Use of igf-ii/igf-iie binding proteins for the treatment and prevention of systemic sclerosis-associated pulmonary fibrosis
US8163509B2 (en) 2008-10-20 2012-04-24 The Regents Of The University Of Colorado, A Body Corporate Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CN102232087A (zh) 2008-11-10 2011-11-02 诺瓦提斯公司 修饰的人igf-1/e肽的抗体
EP2350649A4 (en) 2008-11-28 2012-11-14 Abbott Lab STABLE ANTIBODY COMPOSITIONS AND METHODS FOR STABILIZING THE SAME
CN102227226B (zh) 2008-12-12 2015-05-13 贝林格尔.英格海姆国际有限公司 抗igf抗体
WO2010069858A1 (en) 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
WO2010075511A1 (en) 2008-12-23 2010-07-01 Salk Institute For Biological Studies Method of treating neurodegenerative disease
RU2011146339A (ru) 2009-04-16 2013-05-27 Мерк Шарп Энд Домэ Корп. Комбинированная терапия с использованием агента (ов) против igfr и специфических ингибиторов igf-1r
WO2011057064A1 (en) 2009-11-05 2011-05-12 Brian Long Igf1r inhibitor based treatment of prostate cancer
WO2013148568A1 (en) 2012-03-30 2013-10-03 Merck Sharp & Dohme Corp. Igf1 biomarker for igf1r inhibitor therapy
WO2013169611A1 (en) 2012-05-09 2013-11-14 Merck Sharp & Dohme Corp. Compositions and methods for treating breast cancer
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
SI3096792T1 (sl) 2014-01-24 2020-01-31 Boehringer Ingelheim International Gmbh Zdravljenje raka z uporabo antagonista receptorja insulinu podobnega rastnega faktorja (IGF) v kombinaciji z eksemestanom in everolimusom
US20170088609A1 (en) 2015-09-28 2017-03-30 Boehringer Ingelheim International Gmbh Anticancer combination therapy

Also Published As

Publication number Publication date
EP2376116B1 (en) 2015-12-09
CA2740341A1 (en) 2010-06-17
HRP20160190T1 (hr) 2016-03-25
ES2561045T3 (es) 2016-02-24
TW201026327A (en) 2010-07-16
JP5694184B2 (ja) 2015-04-01
PL2376116T3 (pl) 2016-07-29
CN102227226B (zh) 2015-05-13
CO6390042A2 (es) 2012-02-29
UY32317A (es) 2010-07-30
IL212047A0 (en) 2011-06-30
GEP20146119B (en) 2014-07-25
US20150010574A1 (en) 2015-01-08
PE20120415A1 (es) 2012-05-09
CN102227226A (zh) 2011-10-26
US10179810B2 (en) 2019-01-15
US20130230541A1 (en) 2013-09-05
DK2376116T3 (en) 2016-02-29
KR20110094034A (ko) 2011-08-19
CN103396487A (zh) 2013-11-20
KR101827332B1 (ko) 2018-02-09
AR074726A1 (es) 2011-02-09
NZ592151A (en) 2012-10-26
JP2012511315A (ja) 2012-05-24
MX2011006055A (es) 2011-07-04
EA029178B1 (ru) 2018-02-28
JP2015131812A (ja) 2015-07-23
BRPI0923359B8 (pt) 2021-05-25
EP3064219A2 (en) 2016-09-07
BRPI0923359B1 (pt) 2020-09-15
AU2009324296A1 (en) 2010-06-17
ZA201102308B (en) 2011-12-28
AU2009324296B2 (en) 2016-07-28
ECSP11011126A (es) 2011-07-29
SG2014013841A (en) 2014-07-30
RS54423B1 (sr) 2016-04-28
TWI471139B (zh) 2015-02-01
UA105198C2 (ru) 2014-04-25
MY150984A (en) 2014-03-31
ME02377B (me) 2016-06-20
AP2011005719A0 (en) 2011-06-30
CL2011001431A1 (es) 2012-02-17
US8318159B2 (en) 2012-11-27
SG172107A1 (en) 2011-07-28
MA32888B1 (fr) 2011-12-01
SI2376116T1 (sl) 2016-03-31
WO2010066868A3 (en) 2010-09-10
IL212047A (en) 2016-03-31
WO2010066868A2 (en) 2010-06-17
NZ597694A (en) 2013-08-30
BRPI0923359A2 (pt) 2015-07-21
NZ597692A (en) 2013-08-30
AP3371A (en) 2015-07-31
EA201100918A1 (ru) 2012-01-30
HK1158933A1 (zh) 2012-07-27
EP2376116A2 (en) 2011-10-19
CA2740341C (en) 2019-05-07
US20100150940A1 (en) 2010-06-17
CY1117241T1 (el) 2017-04-05
US11299538B2 (en) 2022-04-12
CN103396488A (zh) 2013-11-20
US20190225681A1 (en) 2019-07-25
EP3064219A3 (en) 2016-09-28
HUE026374T2 (en) 2016-05-30
TN2011000299A1 (en) 2012-12-17

Similar Documents

Publication Publication Date Title
AP3371A (en) Anti-IGF antibodies
IL207217A0 (en) Humanized anti-c5ar antibodies
GB0821100D0 (en) Antibodies
EP2241578A4 (en) ANTI-CLDN6 ANTIBODIES
EP2331579A4 (en) MONOCLONAL ANTIBODIES
IL214996A0 (en) Anti-bcma antibodies
GB0920127D0 (en) Antibodies
GB0909906D0 (en) Antibodies
ZA201102119B (en) Improved antibody libraies
IL229512A (en) Anti-vegf antibodies
EP2427496A4 (en) ANTI-VEGF-D ANTIBODIES
IL217919A0 (en) Humanized anti-cdcp1 antibodies
ZA201202227B (en) Monoclonal antibodies
IL207581A0 (en) Anti-tyrp1 antibodies
IL236236A (en) Antibodies to the fam26f polypeptide
GB0920324D0 (en) Antibodies
GB0905972D0 (en) Antibodies against IL-17BR
ZA201007976B (en) Anti-pirb antibodies
EP2499256A4 (en) ANTI-C-MPL ANTIBODIES
GB0818356D0 (en) Antibodies
GB0911770D0 (en) Antibody
GB0823562D0 (en) Antibodies
GB0806230D0 (en) Antibodies
GB0817622D0 (en) Antibody
GB0817621D0 (en) Antibody